Li Yan-bing, Liu Juan, Liao Zhi-hong, Liao Ying, Deng Wan-ping, Weng Jian-ping
Department of Endocrinology, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.
Zhonghua Yi Xue Za Zhi. 2005 Sep 14;85(35):2472-6.
To compare the efficacy of insulin aspart and human soluble insulin used in insulin pump therapy on the islets beta cell function in newly diagnosed type 2 diabetic patients.
Fifty-nine hospitalized newly diagnosed type 2 diabetic patients, 35 males and 24 females, aged 51 +/- 12, were and randomly divided into 2 groups to undergo insulin pump therapy with insulin aspart (aspart group, n = 30) or human soluble insulin (human insulin group, n = 29) for 2 weeks. The targets of glycemic control included fasting blood glucose (FBG) < 6.1 mmol/L and 2 h postprandial blood glucose (PBG) < 8.0 mmol/L. The changes of blood glucose, and the time and the doses of insulin needed for good glycemic control were compared between the two groups. The frequency of hypoglycemia and pump-related side effects were recorded.
On the 2nd day of insulin pump therapy, FBG and 3 meals PBG levels were significantly reduced in both groups while the post-breakfast and post-dinner blood glucose levels were far more decreased in the aspart group than in the human insulin group (8.4 mmol/L +/- 2.8 mmol/L vs 11.3 mmol/L +/- 3.8 mmol/L, and 9.0 mmol/L +/- 2.4 mmol/L vs 10.7 mmol/L +/- 2.8 mmol/L, both P < 0.05). The FBG and 3 meals PBG were significantly lowered in the aspart group than in the human insulin group on the 7th day and after the stopping of insulin pump therapy. The time of good glycemic control of the aspart group was 2.0 d, significantly shorter than that of the human insulin group (6.0 d, P < 0.01). The mean dose of insulin used during insulin pump therapy in the aspart group was 0.6 U/kg, significantly less than that in the human insulin group (0.8 U/kg, P = 0.002). There was no significant difference in the AIR, mean area under the curve (AUC) of insulin and C peptide during IVGTT, HOMA-beta and proinsulin between the two groups before and after insulin pump therapy. No pump-related side effects were observed in both groups.
In newly diagnosed type 2 diabetic patients with short term insulin pump therapy, the use of insulin aspart was more effective and faster with less doses of insulin in acquiring good glucose control compared with humulin R.
比较门冬胰岛素和人可溶性胰岛素在胰岛素泵治疗中对新诊断2型糖尿病患者胰岛β细胞功能的疗效。
59例住院新诊断2型糖尿病患者,男35例,女24例,年龄51±12岁,随机分为2组,分别采用门冬胰岛素(门冬胰岛素组,n = 30)或人可溶性胰岛素(人胰岛素组,n = 29)进行胰岛素泵治疗2周。血糖控制目标为空腹血糖(FBG)<6.1 mmol/L,餐后2小时血糖(PBG)<8.0 mmol/L。比较两组血糖变化、达到良好血糖控制所需的胰岛素时间和剂量。记录低血糖发生频率及与泵相关的副作用。
胰岛素泵治疗第2天,两组FBG及三餐后PBG水平均显著降低,而门冬胰岛素组早餐后和晚餐后血糖水平下降幅度远大于人胰岛素组(8.4 mmol/L±2.8 mmol/L对11.3 mmol/L±3.8 mmol/L,9.0 mmol/L±2.4 mmol/L对10.7 mmol/L±2.8 mmol/L,均P<0.05)。门冬胰岛素组在第7天及胰岛素泵治疗停止后,FBG及三餐后PBG均显著低于人胰岛素组。门冬胰岛素组达到良好血糖控制的时间为2.0天,显著短于人胰岛素组(6.0天,P<0.01)。门冬胰岛素组胰岛素泵治疗期间平均胰岛素用量为0.6 U/kg,显著低于人胰岛素组(0.8 U/kg,P = 0.002)。两组胰岛素泵治疗前后IVGTT期间的胰岛素抵抗指数(AIR)、胰岛素和C肽曲线下平均面积(AUC)、HOMA-β及胰岛素原无显著差异。两组均未观察到与泵相关的副作用。
在新诊断的2型糖尿病患者短期胰岛素泵治疗中,与正规胰岛素相比,使用门冬胰岛素在获得良好血糖控制方面更有效、起效更快且胰岛素用量更少。